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Abstract
Recent studies have led to the recognition of the epidermal growth factor receptor HER3 as a key player in cancer, and
consequently this receptor has gained increased interest as a target for cancer therapy. We have previously generated
several Affibody molecules with subnanomolar affinity for the HER3 receptor. Here, we investigate the effects of two of
these HER3-specific Affibody molecules, Z05416 and Z05417, on different HER3-overexpressing cancer cell lines. Using flow
cytometry and confocal microscopy, the Affibody molecules were shown to bind to HER3 on three different cell lines.
Furthermore, the receptor binding of the natural ligand heregulin (HRG) was blocked by addition of Affibody molecules. In
addition, both molecules suppressed HRG-induced HER3 and HER2 phosphorylation in MCF-7 cells, as well as HER3
phosphorylation in constantly HER2-activated SKBR-3 cells. Importantly, Western blot analysis also revealed that HRG-
induced downstream signalling through the Ras-MAPK pathway as well as the PI3K-Akt pathway was blocked by the
Affibody molecules. Finally, in an in vitro proliferation assay, the two Affibody molecules demonstrated complete inhibition
of HRG-induced cancer cell growth. Taken together, our findings demonstrate that Z05416 and Z05417 exert an anti-
proliferative effect on two breast cancer cell lines by inhibiting HRG-induced phosphorylation of HER3, suggesting that the
Affibody molecules are promising candidates for future HER3-targeted cancer therapy.
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Introduction
The Epidermal growth factor receptor (EGFR) family of
receptor tyrosine kinases consists of four members: EGFR (ErbB1),
HER2 (ErbB2), HER3 (ErbB3) and HER4 (ErbB4). Binding of
extracellular growth factors induces receptor homo- or hetero-
dimerisation and activation of the intracellular tyrosine kinase
domains, triggering downstream signalling cascades. The signal-
ling eventually leads to proliferation, migration and resistance to
apoptosis [1]. Hence, aberrant regulation of the receptor signalling
contributes to development of various malignancies such as breast,
ovarian, head and neck and lung cancer among others [2]. The
most well-characterised receptors of this family are EGFR and
HER2, which are both overexpressed in a number of cancer types,
respectively. Inhibitors to these two receptors have been developed
as cancer therapeutics during the last years, including receptor-
specific antibodies and low molecular weight tyrosine kinase
inhibitors [3]. Recently, the HER3 receptor has gained interest as
a potential new target of cancer therapy [4,5]. HER3 differs from
the other receptor members in that it lacks a fully functional
tyrosine kinase domain [6], but it has two natural ligands,
heregulin (or neuregulin 1) and neuregulin 2 [7]. Upon ligand
binding, HER3 heterodimerises with other receptors of the EGFR
family, forming a functional signalling unit. EGFR, HER2 and
HER4 are all possible dimerisation partners of HER3, but HER2
and HER3 form a particularly potent heterodimer, which is
regarded as an oncogenic unit in many HER2-driven breast
cancers [8,9]. In these cancers, functionality of both HER2 and
HER3 has been shown essential to maintain tumour proliferation.
HER2 lacks ligands of its own, but is more resistant to
internalisation and degradation than the other receptors [10].
HER3, on the other hand, is unique in that it has a number of
direct binding sites for the p85 subunit of phosphoinositide-3-
kinase (PI3K), which enables more efficient signalling via the
PI3K-AKT pathway compared to the other EGFRs [11]. It is
considered that downregulation of this signalling pathway, which
mediates tumour cell proliferation and survival, is important for
anti-proliferative effects of therapeutic agents targeting the
epidermal growth factor receptors [12,13,14].
Although therapy against EGFR and HER2 has been successful
in many cases, patients have a tendency to develop resistance to
the inhibitory agents [15]. It has been shown that over-activation
of HER3 accounts for some of this resistance, either via increased
receptor phosphorylation and cell surface localisation [16], or via
overexpression of the receptor or upregulation of the ligands,
forming an autocrine loop [17,18]. Therefore, the HER3 receptor
is an interesting target for new antitumour therapeutics and
currently two antibodies against HER3, MM-121 (Merrimack
Pharmaceuticals) and U3-1287 (AMG888, U3 Pharma GmbH/
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the MM-121 anti-HER3 antibody that is under development by
Merrimack Pharmaceuticals is formatted as an IgG2 antibody,
thus unable to induce significant antibody-dependent cellular
cytotoxicity (ADCC) and relies on heregulin (HRG) blocking for
therapeutic effect, indicating that non-immunoglobulin based
binders may have potential for similar applications. Additionally,
a bispecific antibody against both HER2 and HER3, MM-111
(Merrimack Pharmaceuticals), as well as a bispecific antibody
against EGFR and HER3 [19], MEHD7945A (Genentech, A
member of the Roche group) are being tested in the clinic (for
more information see www.clinicaltrials.gov).
We have previously described the selection and affinity
maturation of HER3-binding Affibody molecules [20]. Affibody
molecules are small three-helix proteins (approximately 6.5 kDa),
originally derived from one of the subunits of staphylococcal
protein A. Using various display formats such as phage and
staphylococcal display, Affibody molecules can be selected against
a protein of interest [21,22,23]. For instance, display of
recombinant Affibody libraries has generated EGFR- and
HER2-specific Affibody molecules, which have shown promising
results for both tumour imaging and therapeutic applications
[24,25,26,27]. Affibody molecules (like some other alternative
scaffolds) have complementary properties to antibodies, e.g. i)
much smaller size, ii) lack of disulphide bonds and free cysteines,
iii) high stability and solubility and iv) efficient production routes
using prokaryotic hosts and chemical peptide synthesis are
available [22]. The small size results in a much more rapid in
vivo biodistribution through efficient extravasation and tissue
penetration. The small size also enables flexible engineering,
including straightforward construction of bi/multispecific binders,
directed site-specific modification for conjugation of e.g. small
molecular drugs or chelators for subsequent radiolabelling as well
as tailored in vivo half-life through various technologies (e.g.
PEGylation and fusion to albumin-binding domains). The rapid
biodistribution of Affibody molecules also results in extremely high
contrast in in vivo molecular imaging applications, as have
previously been demonstrated in numerous publications with
binders against for example HER2 and EGFR [22].
In this paper, we have investigated the effects of two affinity-
matured HER3-binding Affibody molecules, Z05416 and Z05417,
on several cancer cell lines. As previously described [20], these
Affibody molecules have high sequence similarity, only differing at
4 out of 58 amino acid positions, and both have subnanomolar
affinity (0.8 and 0.7 nM respectively) for HER3. However, it was
not known whether they could exert any receptor antagonizing
effect on living cells, or what effect the difference in amino acid
sequence would have. In the current in vitro studies, specific
receptor binding on cells was shown using flow cytometry and
confocal microscopy. Subsequently, we studied the effects of the
HER3-specific Affibody molecules on receptor signalling and
cellular growth. We show that HRG-induced phosphorylation of
HER3 as well as downstream Akt and Erk-mediated signalling can
be suppressed by Z05416 and Z05417. Ultimately, treatment of
MCF-7 and SKBR-3 cells with Z05416 or Z05417 was shown to
inhibit HRG-induced cell proliferation.
Materials and Methods
Affibody molecules
The affinity maturated, HER3-specific Affibody molecules His-
Z05416-Cys and His-Z05417-Cys were used in this study and are
hereafter referred to as Z05416 and Z05417 respectively [20]. The
Affibody molecules were produced in E. coli and purified by IMAC
as previously described [20]. As a negative control, a Taq-
polymerase binding Affibody, His-Z01155-Cys, was used (here
referred to as ZTaq). Since Taq polymerase is not naturally
occurring in cells, ZTaq is not supposed to bind to or affect cells.
To avoid spontaneous dimer formation through disulfide bonding,
the C-terminal cysteines of all Affibody molecules were blocked by
N-ethylmaleimide according to a previously described protocol
[20].
Cell lines
The human cancer cell lines AU565, SKBR-3 and SKOV-3
were obtained from ATCC (Manassas, VA, USA), while MCF-7
cells were obtained from DSMZ (Braunschweig, Germany). All
cells were cultured in medium supplemented with foetal calf serum
(FCS; 10%), L-glutamine and penicillin/streptomycin. In addition,
the RPMI growth medium for MCF-7 cells was supplemented
with sodium pyruvate and non-essential amino acids. The RPMI
growth medium for AU565 cells (RPMI medium) was also
supplemented with D-glucose, sodium bicarbonate, sodium
pyruvate and HEPES. Both SKBR-3 and SKOV-3 cells were
grown in McCoy’s medium.
Fluorophore-labelling of Affibody molecules
Z05416, Z05417 and ZTaq were labelled with maleimide-
coupled fluorophore via their C-terminal cysteine. Each Affibody
molecule was diluted in phosphate-buffered saline (PBS) to
100 nM and reduced with 20 mM dithiothreitol (DTT) for 1 h
at room temperature. DTT was removed using NAP-5 columns
(GE Healthcare, Uppsala, Sweden) equilibrated in PBS, and five-
fold molar excess of Alexa FluorH 488 C5-maleimide (Invitrogen,
Carlsbad, CA) dissolved in dimethylsulfoxide (DMSO) was added.
After incubation at room temperature for 1 h in dark, unbound
fluorophore was removed using a PD-10 column (GE Healthcare)
equilibrated with PBS. Degree of labelling and protein concen-
tration was determined using a NanoDrop ND-1000 (Thermo
Scientific, Rockford, IL).
Biotinylation of heregulin
Biotinylation of heregulin (HRG, NRG1-b1/HRG1-b1 ECD
domain, R&D Systems, Minneapolis, MN) was performed using
biotin-XX sulfo succinimidyl ester, sodium salt (Invitrogen) in
0.1 M NaHCO3 (pH 8.5). 50 mg of HRG was mixed with a four-
fold molar excess of biotin and incubated for 1 hour at room
temperature. Next, glycine (100 mg/ml) was added to stop the
labelling reaction prior to removal of excess biotin and buffer
exchange using a NAP-5 column (GE Healthcare) equilibrated
with PBS. The protein concentration was determined by
spectrophotometry.
Flow cytometry, blocking with unlabelled Affibody
molecules
Trypsin treated cells (MCF-7, SKBR-3 and SKOV-3, respec-
tively), 500 000 in each tube, were washed with PBS. The cells
were incubated for 15 minutes with PBS or with 15 mMo f
unlabelled Affibody molecule in PBS to assess specific binding.
Corresponding Alexa FluorH 488-labelled Affibody molecules
were then added to a final concentration of 150 nM and incubated
for 90 minutes. After washes in PBS, the cells were analysed using
a BD LSR II flow cytometer (BD Biosciences, San Jose, CA). All
incubations were performed on ice, and a cooled centrifuge and
ice-cold PBS were used for the washes.
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Affibody molecules were used for immunofluorescence staining
of the human carcinoma cell lines AU565, MCF-7, SKBR-3 and
SKOV-3. As a positive control, a polyclonal goat anti-human
HER3 antibody (AF234, R&D systems) was used. All affinity
reagents were diluted in PBS supplemented with 4% FCS and
washing was performed using ice-cold PBS. Approximately 20 000
cells/well were seeded in a 96-well plate with glass bottom and
grown overnight. The next day, cells were washed prior to
addition of Affibody molecules or the HER3-specific antibody at a
concentration of 1.8 and 0.033 mM respectively. After a 1-hour
incubation, cells were washed and a goat anti-Affibody antibody
(0.033 mM, Affibody AB, Solna, Sweden) was added to wells
previously incubated with Affibody molecules and incubated for
1 hour. Subsequently, all binding events were detected by a final
incubation with a chicken anti-goat IgG conjugated with Alexa
FluorH 488 (Invitrogen) at a concentration of 0.013 mM for
1 hour.
In a second experiment, competitional binding between Affi-
body molecules and HRG to AU565 cells was evaluated. Cells
were stained with 100 nM Affibody molecules for 10 minutes
prior to addition of 100 nM biotinylated HRG in 100 nM
Affibody molecules. After 10 minutes, cells were washed and
streptavidin conjugated with Alexa FluorH 488 (4 mg/ml) was
added to each well. As negative controls, HRG was added to cells
preincubated with PBS as well as to cells incubated with Z01155.
As a negative staining control, streptavidin Alexa FluorH 488 was
added to cells not preincubated with either Affibody molecules or
HRG. After completed staining, cells were washed, fixed in
paraformaldehyde for 15 minutes followed by nuclear staining
with (49,6-diamidino-2-phenylindole) DAPI for 5 minutes. Finally,
1xPBS diluted in 85% glycerol was added and the wells were
covered with foil. Cell staining was analysed using a Leica SP5
confocal laser-scanning microscope with a 636, 1,4 NA oil
immersion objective.
Cell treatment and lysis
Cells were seeded in 6-well plates (600 000–800 000/well),
allowed to grow for 24 hours in complete medium and starved for
24 hours in serum-free medium with 0.1% BSA. Heregulin
(0.05 nM; NRG1-b1/HRG1-b1 EGF domain, R&D Systems)
and Affibody molecules (100 nM) were diluted in starvation
medium and cells were treated in duplicates with combinations of
heregulin and Affibody molecules for 10 minutes at 37uC. The
cells were washed twice with ice cold PBS, and lysis buffer (1%
NP-40, 20 mM Tris (pH 8.0), 137 mM NaCl, 10% glycerol,
2 mM EDTA, 1 mM activated sodium orthovanadate, protease
inhibitor cocktail (Sigma, St Louis, MO)) was added to a
concentration of 6.7610
6 cells per ml lysis buffer. The cells were
kept on ice for 30 minutes, detached from the wells with a cell
scraper and centrifuged in eppendorf tubes at 14 000 g at 4uC for
15 minutes. The supernatant from each tube was collected and
used in the phospho-HER2/3 ELISA and Western blot.
Phospho-HER2/3 ELISA
ELISA kits from R&D systems (DuoSetH IC) for detection of
phosphorylated HER2 and HER3, respectively, were used
according to the manufacturer’s instructions and as described
below. 96-well half area plates were coated with an anti-HER2 or
HER3 antibody at 4 mg/ml in PBS at 4uC over night. The plate
was washed and blocked with 1% BSA in PBS for 2 hours at room
temperature. After washing, 25 ml of ‘‘diluent #12’’ (1% NP-40,
20 mM Tris (pH 8.0), 137 mM NaCl, 10% glycerol, 2 mM
EDTA, 1 mM activated sodium orthovanadate) and 25 mlo f
respective cell lysate was added to each well in duplicates. The
plate was incubated for 2 hours, washed and incubated with HRP-
labelled anti phospho-tyrosine antibody, diluted 1:2000 in ‘‘diluent
#14’’ (20 mM Tris, 137 mM NaCl, 0.05% Tween 20, 0.1% BSA,
pH 7.2–7.4), for 2 hours. The plate was washed and substrate was
added (R&D Systems). After 20 minutes, the reaction was stopped
with 2 M H2SO4 and the plate was analysed in an Emax
microplate reader (Molecular Devices) at 450 and 570 nm.
Western Blot
The Western blot was performed as described earlier [28]. In
short, the cell lysates (produced as described above) were run on a
3–8% Tris-Acetated gel (NuPAGE, Invitrogen) and transferred to
a PVDF membrane (0.45 mm, Immobilon, Millipore, Billerica,
MA). The membranes were blocked with 5% BSA in PBS for 2 h
and incubated with antibodies (diluted in 1% BSA in PBS) against
phospho-Akt (Ser473, Cell Signaling Technology, Beverly, MA),
phospho-Erk 1/2 (Thr202/Tyr204, Cell Signaling Technology)
and b-actin (Sigma), respectively, at 4uC over night (anti-P-Akt,
anti-P-Erk) or at room temperature for 2 h (anti-b-actin). After
washes in PBS-T (PBS +0.1% Tween), the membranes were
incubated with HRP-anti-mouse (anti-P-Akt, anti-P-Erk) or HRP-
anti-rabbit (anti-b-actin) antibodies diluted in 1% BSA in PBS for
1 h at room temperature in the dark. After washes in PBS-T, the
membranes were incubated in HRP substrate (Immobilon,
Millipore) for 1 minute and detected in a CCD-camera (Fuji,
Tokyo, Japan).
Cell proliferation assays
The human breast cancer cell lines MCF-7 and SKBR-3 were
cultured for 5 days in medium supplemented with 2% dialysed
FCS (Gibco, Invitrogen) in the presence or absence of Affibody
molecules and HRG (NRG1-b1/HRG1-b1 EGF domain, R&D
Systems) in order to evaluate the effects of these reagents on cell
growth. Cells were seeded in a 96-well plate and the number of
cells per well was 1500 for MCF-7 cells and 3000 for SKBR-3,
unless stated otherwise. After incubation, the amount of living cells
in each well was determined using cell counting kit-8 (CCK-8,
Fluka, Sigma Aldrich) according to the manufacturer’s recom-
mendations and absorbance was measured at 450 nm using a
microplate reader.
The effect of HRG on cells was evaluated by stimulating MCF-
7 cells and SKBR-3 by the addition of a dilution series of ten
different concentrations of HRG (ranging from 1.5 pM to 10 nM)
in 5 replicates.
In a second experiment, Affibody molecules were added to 1500
MCF-7 cells/well or 2000 SKBR-3 cells/well as a 3-fold dilution
series of 10 different concentrations ranging from 20 pM to
400 nM for MCF-7 cells, or 40 pM to 800 nM for SKBR-3 cells.
Each well was also supplemented with 40 pM HRG. Samples
were analysed in four replicates and the obtained data was fitted
by nonlinear regression to a sigmoidal dose response curve
(variable slope) to obtain IC50 values.
In a final setup, cells were incubated in growth medium
supplemented with HRG or Affibody molecules at a final
concentration of 40 pM and 40 nM respectively. Each sample
was analysed in 5 replicates and results were compared to
unstimulated samples (without added HRG or Affibody mole-
cules). Additionally, mean background absorption by the medium
alone was subtracted from all data.
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Flow cytometry
We have previously generated a panel of HER3-specific
Affibody molecules with subnanomolar affinity to recombinant
HER3 [20]. In order to investigate whether two of the Affibody
molecules, exhibiting the highest affinity to the recombinant
receptor in biosensor assays, could bind to native HER3 expressed
on human cancer cell lines, we performed a flow-cytometric
analysis. The results showed that the fluorescently labelled HER3-
specific Affibody molecules (Z05416 and Z05417) bound to the
HER3-positive breast cancer cell lines MCF-7 and SKBR-3, but
not to the HER3-negative/HER2-positive SKOV-3 cell line
(Fig. 1A–B). Furthermore, to assess the specificity of the
interaction, cells were pre-incubated with 100-fold excess of
corresponding, unlabelled Affibody molecules, resulting in com-
plete blocking of the signal from the fluorescent binders. As a
negative control, an Affibody molecule (ZTaq) with affinity for Taq
polymerase was included in the assay. ZTaq did not bind to any of
the cell lines, hence supporting the findings that the new HER3
binders interacted specifically with HER3 receptors on these
different cell lines.
Immunofluorescence microscopy
To verify the results from the flow-cytometric analysis, cell
binding of the HER3-specific Affibody molecules was investigated
by immunofluorescent staining of four human cancer cell lines and
subsequent confocal microscopy imaging. In addition to the MCF-
7 and SKBR-3 cells that were analysed in the flow cytometry
assay, the HER3-positive breast cancer cell line AU565 and
HER3-negative ovarian cancer cell line SKOV-3 was included. A
HER3-specific antibody was used as a positive control. The images
of the HER3-positive cells incubated with both Affibody
molecules, respectively, revealed a similar staining as for the
antibody, with a speckled pattern mainly localised to the cell
membrane (Fig. 2). In contrast, the analysis of the HER3-negative
and HER2-positive cell line (SKOV-3), as well as the analysis of all
cells incubated with the negative control Affibody molecule
(ZTaq), showed only weak background fluorescence, further
confirming that the cell staining was HER3-specific (Fig. 2).
Blocking of HRG binding to HER3-overexpressing cells
To investigate if the Affibody molecules were able to block the
interaction of the natural ligand heregulin with HER3-overex-
pressing cells and hence potentially inhibit signalling, a competi-
tion assay was conducted using confocal microscopy. HER3-
positive AU565 cells were preincubated with unlabelled Affibody
molecules prior to addition of equimolar amounts of fluorescently
labelled HRG. Using confocal microscopy, images were obtained
for cells preincubated with Affibody molecules as well as for cells
that were only incubated with labelled HRG. The results showed
that first of all, addition of labelled HRG resulted mainly in cell
membrane staining of the HER3-positive cells and second,
preincubation with unlabelled Affibody molecules dramatically
decreased the fluorescence from the HRG-binding (Fig. 3).
Preincubation with the negative control Affibody molecule (ZTaq)
had no significant effect on the HRG-binding, demonstrating that
the HER3-specific Affibody molecules are able to bind to the
HER3 receptor on the cell surface and thereby block the binding
of the natural ligand HRG (Fig. 3). Incubation of cells with only
streptavidin conjugated with Alexa FluorH 488 did not give any
cellular staining (data not shown).
Receptor phosphorylation, ELISA
Epidermal growth factor receptors signal through phosphory-
lation of their intracellular domains as a result of extracellular
receptor dimerisation. Since our new HER3-specific Affibody
molecules were shown to block the binding of HRG to the HER3
receptor and thereby potentially inhibit receptor activation, we
wanted to investigate if binding of the Affibody molecules could
also have an effect on receptor phosphorylation. The level of
phosphorylation of both the HER2 and the HER3 receptors was
analysed in a sandwich ELISA using phosphotyrosine-specific
detection antibodies. Two HER3-overexpressing cell lines (MCF-7
and SKBR-3) were used in the assay. Although the cell lines have
similar HER3 expression levels, expression of HER2 is around
100-fold higher on SKBR-3 cells. As expected, stimulating both
cell lines with the addition of HRG resulted in a significant
increase in HER3 tyrosine phosphorylation levels (Fig. 4B and
4D). Notably, the basal level of HER3-phosphorylation was
considerably higher for SKBR-3 cells compared to MCF-7 cells.
Interestingly, when treated with 100 nM of either HER3-specific
Affibody molecule, the HRG-induced phosphorylation was clearly
reduced towards the same level as for unstimulated cells (Fig. 4B
and 4D). The same pattern was seen in the case of HER2
phosphorylation of MCF-7 cells, although the blocking effect by
the HER3-specific Affibody molecules was less pronounced
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Figure 1. Cell binding of HER3-specific Affibody molecules
analysed by flow cytometry. Binding of Alexa FluorH 488-labelled
Affibody molecules (150 nM) to: A. MCF-7, B. SKBR-3 and the HER3-
negative cell line SKOV-3. ‘‘Bl’’ = blocking with 15 mMo ft h e
corresponding, non-labelled Affibody. MCF-7 cells were stained in a
separate experiment, whereas SKBR-3 and SKOV-3 were stained
simultaneously.
doi:10.1371/journal.pone.0040023.g001
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in contrast, constantly high and not significantly affected by HRG
or the Affibody molecules (Fig. 4C), potentially due to the fact that
SKBR-3 cells express around 100-fold more HER2 receptor
compared to MCF-7. As expected, the negative control ZTaq
Affibody molecule did not affect HER3 or HER2 phosphorylation
(Fig. 4).
Figure 2. Immunofluorescent staining of human cancer cell lines. Images showing AU565, SKBR-3, MCF-7 and SKOV-3 cells stained with
HER3-specific Affibody molecules Z05416 and Z05417, respectively. The polyclonal anti-HER3 antibody A234 and ZTaq were used as positive and
negative staining controls, respectively. Affibody molecules and antibodies binding to cells are shown in green while nuclear staining by DAPI is
given in blue. AU565 and SKOV-3 images were acquired on the same day using the same detection gain and laser power, enabling comparison
between staining intensities. Cell staining of MCF-7 and SKBR-3 was analysed on different days, using different detection gains for optimal image
acquisition. Additionally, MCF-7 images were acquired using increased laser power.
doi:10.1371/journal.pone.0040023.g002
Figure 3. Competitional binding between the natural ligand HRG and Affibody molecules to the HER3-positive breast cancer cell
line AU565 visualised by confocal microscopy. AU565 cells were pretreated with Affibody molecules (Z05416, Z05417 or ZTaq) or PBS only
(HRG) before addition of HRG in conjugation with a fluorophore. HRG binding to cells is shown in green while nuclear staining by DAPI is shown in
blue.
doi:10.1371/journal.pone.0040023.g003
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The two most important downstream signalling pathways for
the epidermal growth factor receptors are the Ras-MAPK and
PI3K-Akt pathways. To investigate potential effects of the HER3-
specific Affibody molecules on these pathways, two proteins
involved in the signalling were studied using Western blot: Erk in
the Ras-MAPK pathway and Akt in the PI3K-Akt pathway. As in
the receptor phosphorylation assay, the two HER3-positive cell
lines MCF-7 and SKBR-3 were included in the analysis. In MCF-
7 cells, both Akt and Erk were shown to be activated by 0.05 nM
HRG, and more interestingly, this activation could be blocked by
addition of the HER3-specific Affibody molecules (Fig. 5). The
results were however slightly different for the SKBR-3 cell line.
Addition of HRG resulted only in phosphorylation of Erk whereas
the phosphorylation of Akt was high even without HRG and no
significant effect could be detected upon HRG stimulation (Fig. 5).
These results are in line with the observed pattern from the
receptor phosphorylation assay, where SKBR-3 cells demonstrat-
ed a constantly high activation of HER2 with only a minor
response to HRG treatment, probably again due to the high
surface expression levels of HER2 on SKBR-3 cells compared to
MCF-7. The HER3-specific Affibody molecules could block the
HRG-induced phosphorylation of Erk also in SKBR-3, however
no effect was seen for the constantly activated Akt (Fig. 5).
Furthermore, adding the negative control Affibody molecule
(ZTaq) did not result in any detectable decrease in phosphoryla-
tion in the assays, supporting the findings that the HER3-specific
binding and particularly blocking of HRG is causing the effect on
Akt and Erk (Fig. 5). Importantly, even though the Affibody
molecules are binding to an epitope on HER3 that is probably
overlapping with the epitope of HRG, neither binder demonstrat-
ed any detectable agonistic effect on Akt or Erk (Fig. 5). Actin
staining showed that all lysates contained similar amounts of
protein (Fig. 5).
Cell proliferation assays
The observed reduction of HRG-induced HER3 and HER2
receptor phosphorylation as well as the effect on the downstream
signalling proteins Akt and Erk, motivated the investigation of
potential growth inhibitory effects of Z05416 and Z05417.
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Figure 4. Analysis of receptor phosphorylation of MCF-7 and SKBR-3 cells. Histograms showing ELISA absorbance results for detection of:
A. Phospho-HER2 in MCF-7 cells, B. Phospho-HER3 in MCF-7 cells, C. Phospho-HER2 in SKBR-3 cells and D. Phospho-HER3 in SKBR-3 cells. Cells were
incubated without HRG (grey bars) or with 0.05 nM HRG (black bars), in combination with the Affibody molecules (100 nM) before being lysed and
analysed in an ELISA.
doi:10.1371/journal.pone.0040023.g004
Figure 5. Western blot analysis of phosphorylated Akt and Erk
upon addition of heregulin and/or HER3-specific Affibody
molecules. Phospho-Akt and phospho-Erk detected by western blot of
cell lysates from MCF-7 and SKBR-3 cells treated with (+) or without (2)
0.05 nM heregulin (HRG) and 100 nM Affibody molecules (Z). As a
control, b-actin was detected to show that the protein concentrations
of the different lysates were equivalent.
doi:10.1371/journal.pone.0040023.g005
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molecules, we verified potential growth stimulatory effect of HRG
on MCF-7 and SKBR-3 cells in a 5-day proliferation assay. In the
assay, HRG was shown to induce growth of both MCF-7 and
SKBR-3 cells in a concentration-dependent manner (Fig. 6A).
Interestingly, for SKBR-3 cells, the ligand demonstrated an anti-
proliferative effect at concentrations of HRG above approximately
0.12 nM (Fig. S1). These results are consistent with previous
findings, where HRG have been demonstrated to have a
concentration-dependent, biphasic stimulatory/anti-proliferative
effect on HER2-overexpressing breast cancer cell lines [29,30,31].
The EC50 values obtained here were 17 pM for MCF-7 cells and
2.7 pM for SKBR-3 cells (for SKBR-3 cells the highest HRG
concentrations were disregarded in the fitting).
In order to further evaluate the effect of HER3-specific Affibody
molecules on the HRG-induced growth of MCF-7 and SKBR-3,
cells were cultivated in a fixed concentration of HRG and a
dilution series of Affibody molecules for 5 days. Determination of
the cell concentration after the 5-day period revealed that the
addition of either Z05416 or Z05417 reduced the HRG-induced
growth of both MCF-7 and SKBR-3 cells in a concentration-
dependent manner and completely blocked the growth-promoting
effects of HRG at high Affibody concentrations (Fig. 6B). The
obtained IC50 values for Z05416 and Z05417 were 19 and 15 nM
respectively for the MCF-7 cell line, and 73 nM and 65 nM
respectively for SKBR-3 cells. The results from the phosphoryla-
tion studies of Erk and Akt (Fig. 5), suggest that the Affibody-
mediated anti-proliferative effect that is observed for SKBR-3 cells
is mainly the result of disrupting the Ras-MAPK pathway,
potentially due to inhibition of HER3-EGFR dimer formation.
Additionally, micromolar concentrations of ZTaq resulted in a
slight decrease in proliferation, potentially due to non-specific
interactions at high concentrations (Fig. 6B).
Finally, to further investigate the mechanisms behind the
growth inhibitory effect of the HER3-specific binders, the two
cancer cell lines were treated with Affibody molecules without
simultaneous stimulation with HRG. Incubation of cells with
40 nM of Affibody molecules alone showed no significant effect on
cellular growth for either cell line, hence supporting the findings
that the Affibody molecules affect the growth rate of the HER3-
overexpressing cells by binding to HER3 and thus blocking HRG-
induced proliferation (Fig. 6C).
Discussion
The recognition of HER3 as a co-inducer of tumour
development, as well as its importance in the context of resistance
against HER2 or EGFR-targeted therapies, has lead to increased
efforts in finding a way to block the activity of this receptor. In this
work, we show that two HER3-specific Affibody molecules,
Z05416 and Z05417, are able to block HRG-induced proliferation
of the HER3-overexpressing breast cancer cell lines MCF-7 and
SKBR-3 in vitro. In the proliferation assays, there were no
Affibody-mediated effects in the absence of HRG, and altogether
these observations suggest that Z05416 and Z05417 exert an anti-
proliferative effect on cells due to their ability to block the
interaction between HER3 and HRG.
These results are promising for future therapeutic targeting of
cancers dependent on the HRG-HER3 signalling pathway.
Blocking of ligand-induced signalling of HER3 has previously
been proven a successful approach for inhibition of tumour cell
growth in in vitro studies of several different cancers. For instance,
the monoclonal antibody pertuzumab inhibits HER2-HER3
heterodimerisation and hence reduces HRG-induced proliferation
of both breast and prostate cancer cells in vitro and in vivo [32].
Additionally, disruption of signalling through a HRG/HER3
autocrine loop in ovarian cancer cells, by RNAi targeting either
HRG or HER3, has been shown to successfully reduce
proliferation of the investigated cell lines [33].
The cellular mechanism by which the HER3-specific Affibody
molecules affect proliferation can be explained by the in vitro
phosphorylation patterns of HER3 and HER2. Here, the
competition between the HER3-specific Affibody molecules and
HRG for HER3 binding was shown to suppress HRG-induced
phosphorylation (activation) of HER3 in both MCF-7 cells and
SKBR-3 cells. In MCF-7 cells, HER2 phosphorylation was
induced by HRG as well and blocked by Z05416 and Z05417,
but in SKBR-3 cells this receptor was constantly active and not
affected by either HRG or the Affibody molecules. SKBR-3 is
known to express extreme amounts of HER2, a feature often
linked to constantly activated receptors [34]. MCF-7 and SKBR-3
are both considered to overexpress HER3, but this generally
means lower amounts of receptors (40 000–50 000) in comparison
to EGFR and HER2-overexpressing cells which may have more
than 10
6 receptors per cell. According to Aguilar et al, the amount
of HER2 per cells is reported to be approximately 2610
6 in
SKBR-3, whereas in MCF-7 it is only 1.5610
4. The HER3
density is 2.5610
4/cell in MCF-7 and 1.3610
4 in SKBR-3 [35].
Two main routes of signalling downstream of HER2 and HER3
are the Ras-MAPK and the PI3K-Akt pathways, which were both
investigated via detection of phosphorylated Akt and Erk (MAPK).
Since HER3 signals mainly via the PI3K-Akt due to its many
PI3K binding sites, this pathway was expected to be most affected
by HRG treatment and Affibody-mediated HER3 blocking.
However, both Akt and Erk were phosphorylated by HRG
treatment in MCF-7 cells, and this phosphorylation was inhibited
by Z05416 and Z05417. A similar pattern was seen for Erk in
SKBR-3 cells, but in these cells Akt was phosphorylated already in
unstimulated cells. This has also been reported by other groups
and is believed to be the result of ligand-independent receptor
dimerisation due to HER2 overexpression [13,36]. Thus, our
results show that HRG-induced SKBR-3 proliferation may be
inhibited by the HER3-binding Affibody molecules without
inactivation of the PI3K-Akt pathway.
Specific HER3 binding of Z05416 and Z05417 was demon-
strated using both flow cytometry and fluorescence microscopy
assays. The moderate intensity of the signals was in concordance
with the relatively low amounts of HER3 on the investigated cell
lines, as discussed above. With this in mind, high-affinity binders
are probably required for successful tumour imaging. The
molecules investigated in this study might therefore be suitable
for potential therapeutic approaches in cancer. Taken together,
the results presented here are promising, and support additional
studies of the effect of Z05416 and Z05417 on tumour growth in
xenografted mice, to further evaluate the therapeutic potential of
these Affibody molecules in vivo. In the future, HER3-specific
Affibody molecules may be useful in treatment of cancers where
the HER3/HRG signalling is involved, potentially in combination
with EGFR or HER2-targeted therapies. An interesting field in
the context of dual tumour targeting is the generation of bispecific
affinity proteins, an approach proven suitable for Affibody
molecules [37]. Evaluation of bispecific Affibody molecules
targeting HER3 in combination with other receptors of the
HER-family would be of great interest due to the complex
signalling of these receptors and the importance of HER3 in the
context of cancer. To summarize, two previously developed
HER3-specific Affibody molecules, with subnanomolar affinity for
recombinant HER3, were investigated in this study in terms of
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results demonstrated that the new binders recognized native
HER3 on several cancer cell lines, blocked the natural ligand
heregulin from binding to the receptor on the cell surface,
decreased the phosphorylation of HER2 and HER3 as well as the
downstream signalling proteins Erk and Akt, and finally, inhibited
the heregulin-induced proliferation of two HER3-positive cancer
cell lines.
Figure 6. Analysis of cellular growth inhibitory effects of the HER3-specific Affibody molecules. Mean absorbance values at 450 nm 6
SD, which is proportional to the number of living cells, is given on the y-axis. A. Proliferation of MCF-7 and SKBR-3 cells grown in a dilution series of
HRG. B. Proliferation of MCF-7 and SKBR-3 cells grown in 40 pM HRG and a dilution series of Affibody molecules Z05416, Z05417 or ZTaq. C.
Proliferation of cells grown in medium containing 40 nM Affibody molecules, 0.04 nM HRG. Results are compared to unstimulated cells (no Affibody
molecules or HRG added).
doi:10.1371/journal.pone.0040023.g006
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Figure S1 Analysis of SKBR-3 cell proliferation in
presence of HRG. Mean absorbance values at 450 nm 6 SD,
which is proportional to the number of living cells, is given on the
y-axis. Proliferation of SKBR-3 cells grown in a dilution series of
HRG. The bell-shaped curve demonstrates a biphasic effect of
HRG on cell growth in a concentration dependent manner.
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